Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anna Ignatova
Observed names:
A. K. Ignatova,
A.K. Ignatova,
Anna K Ignatova,
Anna K. Ignatova
Institutions:
St. Jude Children's Research Hospital,
Ministry of Health of the Russian Federation,
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Observed institutions:
St. Jude Children's Research Hospital,
Sechenov University,
Ministry of Health of the Russian Federation,
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
ORCID:
0000-0002-2968-4499
Observed ORCID:
0000-0002-2968-4499
OpenAlex ID:
A5067841530
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH
2023
·
Dmitry Evseev
, Daria Osipova
, et al.
·
Blood Advances
·
41
PDF
Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA
2021
·
Dmitry Evseev
, Irina Kalinina
, et al.
·
International Journal of Hematology
·
33
PDF
Development of a centralised triage centre for children with cancer and blood disorders in response to the humanitarian crisis in Ukraine
2023
·
Marta Salek
, Alexandra Mueller
, et al.
·
The Lancet Oncology
·
16
Perspectives of pharmacogenetics approach to personalized tamoxifen therapy
2017
·
Marina I. Savelyeva
, Julia S. Panchenko
, et al.
·
World Journal of Personalized Medicine
·
7
Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases
2023
·
E. V. Volchkov
, A. A. Khozyainova
, et al.
·
npj Systems Biology and Applications
·
5
PDF
Clinical characteristics and prognostic significance of extramedullary involvement in childhood acute myeloid leukemia
2021
·
A. K. Ignatova
, I. I. Kalinina
, et al.
·
Oncohematology
·
4
PDF
Ab0987 Choice and Switch Between Biological Agents in Non-systemic Juvenile Idiopathic Arthritis (jia)
2019
·
Anna Ignatova
, Nina Seylanova
, et al.
·
Annals of the Rheumatic Diseases
·
3
PDF
Selection and Switching of Genetically Engineered Biological Agents in Treatment of Juvenile Arthritis
2018
·
E.S. Zholobova
, A.K. Ignatova
, et al.
·
PEDIATRIA Journal named after G N SPERANSKY
·
3
Thiopurine-induced myelotoxicity in patients with acute leukemia and benefits of preemptive pharmacogenetic testing prior to 6-mercaptopurine prescription
2021
·
A. K. Ignatova
, I. I. Kalinina
, et al.
·
Pediatric Hematology/Oncology and Immunopathology
·
1
PDF
Clinical Features and Results of Therapy in Infants and Children Aged 1 to 3 Years Old With Acute Myeloid Leukemia
2023
·
A.K. Ignatova
, I.I. Kalinina
, et al.
·
PEDIATRIA Journal named after G N SPERANSKY
Clinical Features and Results of Therapy in Infants and Children Aged 1 to 3 Years Old With Acute Myeloid Leukemia
2023
·
A.K. Ignatova
, I.I. Kalinina
, et al.
·
PEDIATRIA Journal named after G N SPERANSKY
Opportunities of the pharmacogenetic approach to personalized tamoxifen breast cancer therapy: case reports
2019
·
Marina I Savelyeva
, Irina A Dudina
, et al.
·
Journal of Modern Oncology
Влияние полиморфизмов гена CYP2C19 на фармакокинетику и фармакодинамику тамоксифена
2017
·
М. И. Савельева
, Anna Ignatova
, et al.
·
Journal of Modern Oncology
Фармакогенетические особенности II фазы биотрансформации тамоксифена: систематический обзор
2017
·
М. И. Савельева
, И. А. Урванцева
, et al.
·
Pharmacogenetics and Pharmacogenomics
Perspectives of pharmacogenetics approach to personalized tamoxifen therapy
2017
·
M.I. Savelyeva
, A.K. Ignatova
, et al.
·
Journal of Modern Oncology
Show more works
View as search
Works count:
15
Citation count:
113
H-index:
5
I10-index:
3
Year
Topic
Type